NASDAQ : CPIX
Cumberland Pharmaceuticals Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 4.69 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 70.27M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 70.27M |
| Enterprise Value | 71.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.98M |
| Shares Outstanding | 14.98M |
| Shares Change (YoY) | +2.64% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 41.94% |
| Owned by Institutions (%) | 16.63% |
| Float | 8.70M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.59 |
| Forward PS | n/a |
| PB Ratio | 4.03 |
| P/TBV Ratio | 4.04 |
| P/FCF Ratio | 102.75 |
| P/OCF Ratio | 94.20 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.61 |
| EV / EBITDA | 64.85 |
| EV / EBIT | n/a |
| EV / FCF | 104.00 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.96 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.42 |
| Debt / FCF | 6.89 |
| Interest Coverage | -6.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -14.39% |
| Return on Assets (ROA) | -2.91% |
| Return on Invested Capital (ROIC) | -15.88% |
| Return on Capital Employed (ROCE) | -10.99% |
| Weighted Average Cost of Capital (WACC) | 4.69% |
| Revenue Per Employee | $503,458 |
| Profits Per Employee | -$124,074 |
| Employee Count | 88 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 4.10 |
Taxes
| Measure | Value |
|---|
| Income Tax | 36,656 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.04 |
| 52-Week Price Change | +44.31% |
| 50-Day Moving Average | 7.12 |
| 200-Day Moving Average | 5.52 |
| Relative Strength Index (RSI) | 35.25 |
| Average Volume (20 Days) | 111,424 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 336,001 |
| Short Previous Month | 348,880 |
| Short % of Shares Out | 2.24% |
| Short % of Float | 3.86% |
| Short Ratio (days to cover) | 8.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 44.30M |
| Gross Profit | 37.64M |
| Operating Income | -3.04M |
| Pretax Income | -3.19M |
| Net Income | -10.92M |
| EBITDA | 1.10M |
| EBIT | -3.04M |
| Loss Per Share | -$0.74 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.86M |
| Total Debt | 4.71M |
| Net Cash | -851,782 |
| Net Cash Per Share | -$0.06 |
| Equity (Book Value) | 17.11M |
| Book Value Per Share | 1.16 |
| Working Capital | -1.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 745,969 |
| Capital Expenditures | -62,070 |
| Depreciation & Amortization | 4.14M |
| Net Borrowing | -5.24M |
| Free Cash Flow | 683,899 |
| FCF Per Share | $0.05 |
Margins
| Measure | Value |
|---|
| Gross Margin | 84.95% |
| Operating Margin | -6.87% |
| Pretax Margin | -7.19% |
| Profit Margin | -24.64% |
| EBITDA Margin | 2.48% |
| EBIT Margin | -6.87% |
| FCF Margin | 1.54% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.64% |
| Shareholder Yield | -2.64% |
| Earnings Yield | -15.77% |
| FCF Yield | 0.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.48 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |